Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that Algernon's CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company's interim data report for part 2b of the Company's Phase 2b3 clinical study of Ifenprodil for COVID-19 on an upcoming Streetsmart Live! webcast. They will be joined by Dr. Mark Swaim, founder of BIOPUB and Steve Palmer, President and CEO of AlphaNorth Asset Management, as they also discuss upcoming catalysts and events.

The Streetsmart Live! webcast will be held Monday December 21, 2020 hosted at noon EST. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.

Please click the link below to join the webinar:

https://www.streetwisereports.com/events/register/?event_id=69&utm_source=AGN_PR

About Streetwise Reports

Since 2001, Streetwise Reports has been the place where investors go to read about promising investment ideas straight from leading industry experts, analysts, newsletter writers and money managers.

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com  
  investors@algernonpharmaceuticals   .com
  www.algernonpharmaceuticals.com .

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Sort by
Cizzle Brands Unveils its Team of Ambassadors to Accelerate North American Commercialization Initiatives

Cizzle Brands Unveils its Team of Ambassadors to Accelerate North American Commercialization Initiatives

Through a curated team of the world's most experienced and qualified dieticians, performance coaches, scientists, and medical professionals who are subject matter experts in their respective fields, Cizzle Brands is building a house of brands in the sports nutrition industry that serves the world's most elite athletes and leverages that knowledge to make products for everyday people looking to live healthy, active lifestyles. Cizzle Brands' ambassadors will not only assist in product development and formulation but they will also help to expand knowledge and adoption of Cizzle Brands' products around the world.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Scientist using microscope.

Biotech Market Update: Q3 2024 in Review

The biotech sector in Q3 2024 experienced a dynamic landscape characterized by advancements in AI-powered drug discovery and fluctuating venture capital investments.

Investors exercised caution and restraint due to the economic outlook; however, the potential of artificial intelligence (AI) to revolutionize healthcare remained a focal point.

Here, the Investing News Network delves into the key trends and developments that shaped the biotech sector during Q3, highlighting the interplay of innovation, investment, and regulatory considerations.

Keep reading...Show less
Don Saladino, Personal Trainer to Hollywood's A-List, Joins Cizzle Brands as an Advisor

Don Saladino, Personal Trainer to Hollywood's A-List, Joins Cizzle Brands as an Advisor

Hollywood actors, professional athletes, and award-winning musicians alike have all relied on Don Saladino, coach and trainer of over 20 years, to reach their full potential in physical fitness. As an advisor to Cizzle Brands, Mr. Saladino will provide his insights, expertise, and access to his vast professional network for the commercialization and promotion of Cizzle Brands' product lines at a global scale.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

FDA APPROVES LUMAKRAS® IN COMBINATION WITH VECTIBIX® FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that LUMAKRAS plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to show superior progression-free survival (PFS) compared to the investigated standard-of-care (SOC). 1*

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

FDA APPROVES LUMAKRAS® IN COMBINATION WITH VECTIBIX® FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that LUMAKRAS plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to show superior progression-free survival (PFS) compared to the investigated standard-of-care (SOC). 1*

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cizzle Brands Corporation Teams up with Hockey Influencer, Coach Chippy, to launch Tropical Flow, a Special Edition Coach Chippy Inspired Flavour of CWENCH Hydration

Cizzle Brands Corporation Teams up with Hockey Influencer, Coach Chippy, to launch Tropical Flow, a Special Edition Coach Chippy Inspired Flavour of CWENCH Hydration

With a combined social media following of more than one million users, Coach Chippy is a leading influencer in youth hockey. Through his Tropical Flow flavour of CWENCH Hydration, which will be available for purchase at Pro Hockey Life, Source for Sports, Sports Excellence and other leading retailers, Coach Chippy will be creating greater visibility for CWENCH Hydration in a key demographic for the brand.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×